Comparative Clinical Effectiveness of TLD versus TLE Regimens in HIV/AIDS: A Systematic Review
Isi Artikel Utama
Abstrak
Antiretroviral therapy (ART) remains the cornerstone of Human Immunodeficiency Virus (HIV) management. The World Health Organization recommends Tenofovir–Lamivudine–Dolutegravir (TLD) as a preferred first-line regimen in many settings, replacing Tenofovir–Lamivudine–Efavirenz (TLE) because of its favorable virological efficacy, resistance barrier, and tolerability. However, comparative evidence across different patient populations remains heterogeneous. This systematic review aimed to compare the clinical effectiveness of TLD and TLE in patients with HIV/AIDS, focusing on virological suppression, immunological recovery, clinical outcomes, and safety. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 framework. Literature searches were conducted in PubMed, PubMed Central, ScienceDirect, and Google Scholar for studies published from January 2021 to May 2026. Eligible original studies were selected using predefined inclusion and exclusion criteria, and findings were synthesized narratively because of methodological and population heterogeneity. Of 50 records identified, 20 studies were included, covering adults, children, pregnant and lactating women, patients switching therapy, and patients with advanced AIDS. Sample sizes ranged from 102 to 2,599 participants, with follow-up periods of 6–24 months. Overall, most studies reported more favorable virological outcomes with dolutegravir-based regimens. For example, viral suppression at six months was 88.57% versus 55.71% in one adult study, while pediatric and advanced AIDS cohorts also showed higher suppression rates with DTG-based therapy. Several studies reported greater CD4+ recovery, improved clinical outcomes, better treatment durability, and fewer adverse-event-related regimen changes with TLD or DTG-based regimens. The findings indicate that TLD/DTG-based therapy is consistently associated with favorable virological and immunological outcomes compared with TLE/EFV-based therapy. Nevertheless, heterogeneity and the predominance of observational study designs limit causal interpretation. Prospective and randomized studies with longer follow-up are warranted to strengthen the evidence on long-term effectiveness and safety.
Rincian Artikel
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Referensi
Ayal, M. A., & Berha, A. B. (2023). Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study. HIV/AIDS - Research and Palliative Care, Volume 15, 173–190. https://doi.org/10.2147/HIV.S396420
Brites, C., Lacerda, M., Sprinz, E., Bay, M., Pinto, G., Azevedo, P., Luz, E., Lins-Kusterer, L., & Netto, E. M. (2024). Outcomes of severely ill patients with AIDS treated with efavirenz or dolutegravir: a multicenter, observational study. Frontiers in Medicine, 11, Article 1302710. https://doi.org/10.3389/fmed.2024.1302710
Chan, P., Yoon, B., Colby, D., Kroon, E., Sacdalan, C., Sriplienchan, S., Pinyakorn, S., Ananworanich, J., Valcour, V., Vasan, S., Hsu, D., Phanuphak, N., Paul, R., & Spudich, S. (2023). Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection. Clinical Infectious Diseases, 76(3), e718–e726. https://doi.org/10.1093/cid/ciac466
Chiabi, A., Nykam, S., Kan, K., Fomenky, C., Tanlaka, L. M., Ngueiwoh, F. N., Ewane, C., Fozao, V. M., & Nsame, D. (2025). Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon. Infectious Diseases Now, 55(8), 105185. https://doi.org/10.1016/j.idnow.2025.105185
Doke, N., Hajgude, S., Dhande, A., Tole, S., Gunjegaonkar, S., & Joshi, A. (2024). The clinical efficacy of integrating dolutegravir into the conventional therapeutic regimen for HIV management. International Journal of Pharmaceutical Sciences and Drug Research, 16(6), 940–948. https://doi.org/10.25004/IJPSDR.2024.160603
Dumchev, K., Kiriazova, T., Riabokon, S., Shost, A., Parrish, C., Shapoval, A., Germanovych, M., Penner, J., Beste, J., & Puttkammer, N. (2022). Comparative Clinical Outcomes With Scale-up of Dolutegravir as First-Line Antiretroviral Therapy in Ukraine. JAIDS Journal of Acquired Immune Deficiency Syndromes, 91(2), 197–209. https://doi.org/10.1097/QAI.0000000000003038
Facha, W., Tadesse, T., Wolka, E., & Astatkie, A. (2024). Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study. PLOS ONE, 19(6), e0305331. https://doi.org/10.1371/journal.pone.0305331
Kashyap, M., Verma, A., Pathak, D., Gautam, S., & Gupta, M. (2026). Comparative Analysis of Effectiveness of Dolutegravir-Based Regimen (TLD) vs. Efavirenz-Based Regimen (TLE) to Prevent Mother-to-Child Transmission of HIV. Cureus, 18(1), Article e100824. https://doi.org/10.7759/cureus.100824
Mahale, P. R., Patel, B. S., & Kasmani, N. (2023). Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV. Cureus, 16(6), Article e40139. https://doi.org/10.7759/cureus.40139
Majula, R. T., & Mweya, C. N. (2024). Brief communication: Long-term treatment outcomes of transitioning to dolutegravir-based ART from efavirenz in HIV study participants in Mbeya, Tanzania. AIDS Research and Therapy, 21(1), Article 98. https://doi.org/10.1186/s12981-024-00662-z
Malaba, T. R., Nakatudde, I., Kintu, K., Colbers, A., Chen, T., Reynolds, H., Read, L., Read, J., Stemmet, L.-A., Mrubata, M., Byrne, K., Seden, K., Twimukye, A., Theunissen, H., Hodel, E. M., Chiong, J., Hu, N.-C., Burger, D., Wang, D., … Neary, A. (2022). 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. The Lancet HIV, 9(8), e534–e543. https://doi.org/10.1016/S2352-3018(22)00173-4
Mengistu, E. F., Malik, D. T., Molla, M. D., Adugna, A., & Jemal, M. (2024). Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study. Heliyon, 10(12), e33054. https://doi.org/10.1016/j.heliyon.2024.e33054
Njuguna, C., Maluleke, C., Davies, N., Hans, L., Mutasa, B., & Rees, K. (2025). Viral suppression in adults on efavirenz- or dolutegravir-based antiretroviral therapy in Mopani District, South Africa. Southern African Journal of HIV Medicine, 26(1), Article a1716. https://doi.org/10.4102/sajhivmed.v26i1.1718
Nwachukwu, C. C., Njelita, I. A., Eyisi, G. I., Ezenyeaku, C. A., Nwachukwu, A. C., & Agbata, A. (2023). Efficacy of tenofovir/lamivudine/dolutegravir (tld) in the treatment of HIV in a tertiary care centre in south east NIGERIA. International Journal of Interdisciplinary Research and Innovations, 11(1), 38–43.
Nwachukwu, C. C., Njelita, I. A., Eyisi, G. I., Ezenyeaku, C. A., Nwachukwu, A. C., Okechi, O., & Agbata, A. (2023). Treatment Outcomes for HIV Patients on Three HAART Regimens in South East Nigeria: A Comparative Study. American Journal of Public Health Research, 11(2), 75–83. https://doi.org/10.12691/ajphr-11-2-6
Ramesh, P., & Swathi, M. S. (2025). Clinical outcomes of dolutegravir-based antiretroviral therapy. BioClinix: Journal of Medical and Pharmaceutical Sciences, 1(1), 63–74. https://bioclinixjournal.com/index.php/bio/article/view/12
Sari, P. A. K., Widiastuti, R., & Azmi, N. A. (2025). Analisis Efektivitas Regimen Terapi Antiretroviral terhadap Status Viral Load pada Pasien HIV di Puskesmas Umbulharjo 1 dan Gedongtengen. Indonesian Journal of Pharmacy and Natural Product, 8(01), 70–78. https://doi.org/10.35473/ijpnp.v8i01.4001
Sawry, S., Ayalew, K., Maimela, G., Briggs‐Hagen, M., van Wyk‐Heath, M., Mthethwa, S., Shai, S., Mngomezulu, N. N., Tlhowe, L., Achere‐Darko, J., Bedford, J., Martin, C. E., Fairlie, L., & Imrie, J. (2024). Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane District, South Africa: An observational study. HIV Medicine, 25(7), 826–839. https://doi.org/10.1111/hiv.13638
Silva, G. J. da, Mendicino, C. C. P., Pádua, C. A. M. de, & Tupinambás, U. (2023). Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens. Einstein (São Paulo), 21, Article eAO0156. https://doi.org/10.31744/einstein_journal/2023AO0156
UNAIDS. (2024). Global AIDS update 2024: The urgency of now—AIDS at a crossroads. Joint United Nations Programme on HIV/AIDS.
World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.
Zhong, M., Li, M., Qi, M., Su, Y., Yu, N., Lv, R., Ye, Z., Zhang, X., Xu, X., Cheng, C., Chen, C., & Wei, H. (2023). A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China. Frontiers in Immunology, 13, 2899–2909. https://doi.org/10.3389/fimmu.2022.1033098
Zuhdi, M. N., Halim, R., Alimuddin, S., Bakri, S., Iskandar, H., & Zainuddin, A. (2026). Comparison Of Clinical Stadium Changes And Immunologic Parameter Of Adult HIV patients With Dolutegravir And Efavirenz Based Antiretroviral Therapy. F1000Research, 15, Article 582. https://doi.org/10.12688/f1000research.179310.1